This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/usa/519780-johnson-million-vaccine-doses-ruined/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| 15 MILLION doses of J&J vaccine ruined in ‘ingredient mixup accident’ at Baltimore plant, delaying US shipments & triggering probe | 15 MILLION doses of J&J vaccine ruined in ‘ingredient mixup accident’ at Baltimore plant, delaying US shipments & triggering probe |
| (5 months later) | |
| Deliveries of Johnson & Johnson’s single-shot coronavirus vaccine face delays in the US after a factory mixup tarnished some 15 million doses of the inoculation, prompting a pause on shipments as regulators probe the mishap. | Deliveries of Johnson & Johnson’s single-shot coronavirus vaccine face delays in the US after a factory mixup tarnished some 15 million doses of the inoculation, prompting a pause on shipments as regulators probe the mishap. |
| A manufacturing plant in Baltimore mistakenly used the wrong ingredients in millions of Johnson & Johnson shots several weeks ago, the New York Times reported on Wednesday, noting that US officials are investigating but have so far ruled the incident a result of human error. | A manufacturing plant in Baltimore mistakenly used the wrong ingredients in millions of Johnson & Johnson shots several weeks ago, the New York Times reported on Wednesday, noting that US officials are investigating but have so far ruled the incident a result of human error. |
| Run by Emergent BioSolutions, a Maryland-based biopharmaceutical firm, the plant partners with both J&J and AstraZeneca and produces both companies’ immunizations. | Run by Emergent BioSolutions, a Maryland-based biopharmaceutical firm, the plant partners with both J&J and AstraZeneca and produces both companies’ immunizations. |
| Though the factory mixup triggered a halt on future deliveries of the J&J jab while the Food and Drug Administration evaluates the production line, the pause will not affect doses that are currently being distributed around the US, as the previous batch was produced at a different plant in the Netherlands. Tens of millions of doses were expected to come from the Baltimore facility over the next month, but future shipments are now under scrutiny as federal regulators work out the quality control issues. | Though the factory mixup triggered a halt on future deliveries of the J&J jab while the Food and Drug Administration evaluates the production line, the pause will not affect doses that are currently being distributed around the US, as the previous batch was produced at a different plant in the Netherlands. Tens of millions of doses were expected to come from the Baltimore facility over the next month, but future shipments are now under scrutiny as federal regulators work out the quality control issues. |
| J&J said it would increase its oversight and control over Emergent BioSolutions to avoid similar mistakes in the future, according to the Times. | J&J said it would increase its oversight and control over Emergent BioSolutions to avoid similar mistakes in the future, according to the Times. |
| However, despite the millions of wasted doses, health officials still expect the US to have a sufficient vaccine supply to meet President Joe Biden’s pledge to produce enough shots to inoculate every adult by the end of May. Deliveries will continue for two other federally approved jabs developed by Pfizer-BioNTech and Moderna. The latter company is currently seeking authorization to expand its vaccine vials to pack 15 doses, rather than 10, potentially offsetting the delayed J&J shipments. | However, despite the millions of wasted doses, health officials still expect the US to have a sufficient vaccine supply to meet President Joe Biden’s pledge to produce enough shots to inoculate every adult by the end of May. Deliveries will continue for two other federally approved jabs developed by Pfizer-BioNTech and Moderna. The latter company is currently seeking authorization to expand its vaccine vials to pack 15 doses, rather than 10, potentially offsetting the delayed J&J shipments. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |